Please use this identifier to cite or link to this item:
|Title:||Carbimazole-induced agranulocytosis: does antineutrophil cytoplasmic antibody have a role?||Austin Authors:||Yip, G;Ekinci, Elif I ;Lee, S T;Jerums, George ;Grossmann, Mathis||Affiliation:||Department of Medicine, Austin Health, Heidelberg, Victoria, Australia||Issue Date:||1-Apr-2010||Publication information:||Internal Medicine Journal; 40(4): 300-3||Abstract:||Carbimazole is a drug that is widely used for hyperthyroid disorders, such as Graves' disease. Agranulocytosis is a rare idiosyncratic adverse reaction to the drug which is potentially fatal. This report describes a patient with a history of successfully treated pyoderma gangrenosum, who developed agranulocytosis 3 weeks after commencement of carbimazole for Graves' disease. It may give credence to the theory that implicates antineutrophil cytoplasmic antibodies in the pathogenesis of agranulocytosis induced by antithyroid drugs.||Gov't Doc #:||20529040||URI:||http://ahro.austin.org.au/austinjspui/handle/1/11052||DOI:||10.1111/j.1445-5994.2009.02143.x||URL:||https://pubmed.ncbi.nlm.nih.gov/20529040||Type:||Journal Article||Subjects:||Adult
Antibodies, Antineutrophil Cytoplasmic.biosynthesis.blood.physiology
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 7, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.